| Subject: | FDA MedWatch - Exubera (insulin human rDNA origin) Inhalation Powder - Prescribing Information Updated |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 10 Apr 2008 - 11:00 am |
| Exubera is a short-acting insulin you breathe in through your mouth using the Exubera inhaler that helps to control high blood sugar in adults with diabetes. The Exubera label was updated by Pfizer and the FDA. According to Pfizer's Letter to Healthcare Professionals, the update resulted from Pfizer and the FDA's ongoing safety reporting and review processes related to Pfizer's clinical trials program and post-marketing reports. A new WARNING was added to the Exubera... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
